Evidence map›Paper›PMID 32589451›Full record

ArticleAnnals of internal medicine2020

Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study.

Julia Del Amo, Rosa Polo, Santiago Moreno, Asunción Díaz, Esteban Martínez, José Ramón Arribas, Inma Jarrín, Miguel A Hernán, The Spanish HIV/COVID-19 Collaboration

Registry-linked trialOpen access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of internal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04519125 (Effectiveness of the Use of Personal Protective Equipment in Addition to Tenofovir/Emtricitabine for the Prevention of the Transmission of SARS-COV-2 to Health Care Personnel. Randomized Clinical Trial), which is not on this map. Cited by 180 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
180citing papers in PubMed, 11 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04519125 phase2 / phase3unknown statusnot on this map

Effectiveness of the Use of Personal Protective Equipment in Addition to Tenofovir/Emtricitabine for the Prevention of the Transmission of SARS-COV-2 to Health Care Personnel. Randomized Clinical Trial

TypeinterventionalSponsorHospital Universitario San IgnacioRan2020 to 2021Enrolled950ConditionsSevere Acute Respiratory Syndrome Coronavirus 2, COVID-19ArmsTenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE), Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE)
3 · Its place in the literature

Who cites it

180 citing papers in PubMed, 11 syntheses or guidelines pooled it, 340 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. COVID-19 in People Living with HIV: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2021
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2023
    Trial
  14. Trial
  15. Profile of SARS-CoV-2/HIV-1 coinfection in patients from the extreme south of Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026
    Article
  16. Review
  17. Review
  18. Article
  19. Observational
  20. Article

120 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Julia Del AmoMinistry of Health, Madrid, Spain (J.D., R.P.).
Rosa PoloMinistry of Health, Madrid, Spain (J.D., R.P.).
Santiago MorenoUniversity Hospital Ramón y Cajal and HIV Network of Excellence, Madrid, Spain (S.M.).ORCID 0000-0002-2843-1094
Asunción DíazMinistry of Health, HIV Network of Excellence, and Institute of Health Carlos III, Madrid, Spain (A.D.).ORCID 0000-0002-8309-4270
Esteban MartínezHIV Network of Excellence, Madrid, and University Hospital Clinic, Barcelona, Spain (E.M.).
José Ramón ArribasHIV Network of Excellence and University Hospital La Paz, IdiPAZ, Madrid, Spain (J.R.A.).ORCID 0000-0002-7410-9450
Inma JarrínHIV Network of Excellence and Institute of Health Carlos III, Madrid, Spain (I.J.).
Miguel A HernánHarvard T.H. Chan School of Public Health and Harvard-MIT Division of Health Sciences and Technology, Boston, Massachusetts (M.A.H.).
The Spanish HIV/COVID-19 Collaboration
Instituto de Salud Carlos III · ESMinistry of Health · ESHarvard–MIT Division of Health Sciences and Technology · USHospital La Paz Institute for Health Research · ES

Funding

Dynamic Strategies for the clinical management of HIV diseaseR37AI102634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI MIGUEL HERNAN · 2018 to 2026
$5.3M
Dynamic strategies for the clinical management of HIV diseaseR01AI102634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HERNAN, MIGUEL · 2013 to 2017
$2.6M
NIAID NIH HHS R01 AI102634NIAID NIH HHS R37 AI102634
6 · The paper itself

Abstract

backgroundThe incidence and severity of coronavirus disease 2019 (COVID-19) among HIV-positive persons receiving antiretroviral therapy (ART) have not been characterized in large populations.

objectiveTo describe the incidence and severity of COVID-19 by nucleos(t)ide reverse transcriptase inhibitor (NRTI) use among HIV-positive persons receiving ART.

designCohort study.

settingHIV clinics in 60 Spanish hospitals between 1 February and 15 April 2020.

participants77 590 HIV-positive persons receiving ART. MEASUREMENTS: Estimated risks (cumulative incidences) per 10 000 persons and 95% CIs for polymerase chain reaction-confirmed COVID-19 diagnosis, hospitalization, intensive care unit (ICU) admission, and death. Risk and 95% CIs for COVID-19 diagnosis and hospital admission by use of the NRTIs tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), tenofovir alafenamide (TAF)/FTC, abacavir (ABC)/lamivudine (3TC), and others were estimated through Poisson regression models.

resultsOf 77 590 HIV-positive persons receiving ART, 236 were diagnosed with COVID-19, 151 were hospitalized, 15 were admitted to the ICU, and 20 died. The risks for COVID-19 diagnosis and hospitalization were greater in men and persons older than 70 years. The risk for COVID-19 hospitalization was 20.3 (95% CI, 15.2 to 26.7) among patients receiving TAF/FTC, 10.5 (CI, 5.6 to 17.9) among those receiving TDF/FTC, 23.4 (CI, 17.2 to 31.1) among those receiving ABC/3TC, and 20.0 (CI, 14.2 to 27.3) for those receiving other regimens. The corresponding risks for COVID-19 diagnosis were 39.1 (CI, 31.8 to 47.6), 16.9 (CI, 10.5 to 25.9), 28.3 (CI, 21.5 to 36.7), and 29.7 (CI, 22.6 to 38.4), respectively. No patient receiving TDF/FTC was admitted to the ICU or died. LIMITATION: Residual confounding by comorbid conditions cannot be completely excluded.

conclusionHIV-positive patients receiving TDF/FTC have a lower risk for COVID-19 and related hospitalization than those receiving other therapies. These findings warrant further investigation in HIV preexposure prophylaxis studies and randomized trials in persons without HIV. PRIMARY FUNDING SOURCE: Instituto de Salud Carlos III and National Institutes of Health.

Indexed as

Antiretroviral Therapy, Highly ActiveAbacavirAdenineAdultAgedBetacoronavirusCoronavirus InfectionsCOVID-19DideoxynucleosidesDrug CombinationsEmtricitabineFemaleHIV InfectionsHospitalizationHumansIncidenceAbacavirabacavir, lamivudine drug combinationAdenineDideoxynucleosidesDrug CombinationsEmtricitabineemtricitabine tenofovir alafenamideLamivudineTenofovir

Identifiers

PMID32589451
PMCPMC7394316
OpenAlexW3157063593

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.